Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-intolerance to nilotinib in imatinib-intolerant pati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Cortes, Jorge E., Hochhaus, Andreas, le Coutre, Philipp D., Rosti, Gianantonio, Pinilla-Ibarz, Javier, Jabbour, Elias, Gillis, Kathryn, Woodman, Richard C., Blakesley, Rick E., Giles, Francis J., Kantarjian, Hagop M., Baccarani, Michele
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2011
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186645/
https://ncbi.nlm.nih.gov/pubmed/21467546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-318949
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia